Cullinan Therapeutics, Inc. (CGEM)

23.17 -0.64 (-2.69%) 收市：04:00PM EDT

Cullinan Therapeutics, Inc.

One Main Street
Suite 1350
Cambridge, MA 02142
United States
617 410 4650
https://cullinantherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 85

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Nadim Ahmed	President, CEO & Director	1.16M	無	1968
Dr. Jeffrey Jones M.B.A., M.D., M.P.H.	Chief Medical Officer	780.32k	無	1971
Dr. Patrick A. Baeuerle Ph.D.	Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board	763.73k	無	1958
Ms. Mary Kay Fenton	Chief Financial Officer	無	無	1964
Dr. Jennifer Michaelson Ph.D.	Chief Scientific Officer	無	無	1967
Ms. Jacquelyn L. Sumer J.D.	Chief Legal Officer, Chief Compliance Officer & Corporate Secretary	無	無	1978
Ms. Rose Weldon	Senior Vice President of Communications	無	無	無
Mr. Steve Andre	Chief Human Resources Officer	無	無	無
Dr. Corinne Savill Ph.D.	Chief Business Officer	無	無	1959
Mr. Kevin A. Johnston	Chief Technical Operations Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

公司管治

截至 2024年5月1日 止，Cullinan Therapeutics, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：9；董事會：7；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。